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Requirements for nuclear localization of ERKs haveSummary
been studied in transfected cells. Catalytically defective
mutants and mutants lacking either or both of the two
The MAP kinase ERK2 is widely involved in eukaryotic activating phosphorylation sites tyrosine-185 and threo-
signal transduction. Upon activation it translocates to nine-183 (in ERK2) undergo stimulus-dependent relocal-
the nucleus of the stimulated cell, where it phosphory- ization (Chen et al., 1992; Gonzalez et al., 1993; Lenor-
lates nuclear targets. We find that nuclear accumula- mand et al., 1993). Therefore, nuclear accumulation of
tion of microinjected ERK2 depends on its phosphory- ERKs was presumed to be independent of their activity
lation state rather than on its activity or on upstream and phosphorylation state. An upstream component or
components of its signaling pathway. Phosphorylated a separate stimulus-dependent pathway seemed possi-
ERK2 forms dimers with phosphorylated and unphos- ble regulators of ERK1/2 nuclear localization.
phorylated ERK2 partners. Disruption of dimerization To examine events necessary for ERK nuclear translo-
by mutagenesis of ERK2 reduces its ability to accumu- cation, wild-type and mutant ERK2 proteins were mi-
late in the nucleus, suggesting that dimerization is croinjected into mammalian cells. ERK2, phosphory-
essential for its normal ligand-dependent relocaliza- lated on both tyrosine and threonine, either wild-type
tion. The crystal structure of phosphorylated ERK2 or the kinase-deficient mutant K52R, accumulated in
reveals the basis for dimerization. Other MAP kinase the nucleus. Unphosphorylated ERK2 remained in the
family members also form dimers. The generality of cytoplasm but moved to the nucleus upon coinjec-
tion with phosphorylated ERK2. Phosphorylated ERK2this behavior suggests that dimerization is part of the
formed dimers with phosphorylated and unphosphory-mechanism of action of the MAP kinase family.
lated ERK2 partners. The dimer dissociation constant
(KD) for phosphorylated ERK2 is 7.5 nM, z3000-foldIntroduction
lower than that for unphosphorylated dimers, suggest-
ing that active ERK2 exists as a dimer in cells. Dimeriza-Mitogen-activated protein (MAP) kinases are ubiquitous
tion of unphosphorylated with phosphorylated ERK2 fa-protein kinases involved in signal transduction in eukar-
cilitated import of the unphosphorylated protein andyotic organisms (Hunter, 1995; Karin, 1995; Waskiewicz
may account for the stimulus-dependent translocationand Cooper, 1995; Kyriakis and Avruch, 1996; Lewis et
of mutants lacking phosphorylation sites. The crystalal., 1998; Robinson and Cobb, 1997). Their actions are
structure of phosphorylated ERK2 (Canagarajah et al.,important for a panoply of cellular functions from prolif-
1997) revealed a dimer interface consistent with the bio-eration and development to inflammatory responses
chemical findings. Mutants of ERK2 that were unable toand programmed cell death. The best-studied MAP ki-
dimerize were less able to accumulate in the nucleusnases, extracellular signal-regulated kinases (ERKs) 1
even if phosphorylated.and 2, phosphorylate proteins from the plasma mem-
These studies indicate that the nuclear accumulation
braneto thenucleus (Moriguchi etal., 1996). Localization
of MAP kinase depends on its phosphorylation state
at their sites of action is one determinant of their func-
rather than on its activity. Phosphorylation induces its
tions. In unstimulated cells, ERK1/2 are largely cyto- dimerization, which is required for its nuclear location.
plasmic. Upon activation, both kinases translocate to Other MAP kinase family members also formed dimers
the nucleus in part (Chen et al., 1992, 1996; Gonzalez when phosphorylated. The formation of dimers upon
et al., 1993; Lenormand et al., 1993; Reszka et al., 1995; activation is common to the MAP kinase family and is
Fukuda et al., 1997); quantitation reveals that half of the likely to be an inherent part of their mechanisms of
endogenous ERK2 remains in the cytoplasm, primarily action.
associated with the microtubule cytoskeleton (Reszka
et al., 1995). The duration of activation of MAP kinases Results
influences the extent of their nuclear translocation and,
thus, their access to nuclear substrates such as ternary Phosphorylation of ERK2 Is Sufficient
to Cause Its Nuclear Accumulation
Phosphorylated ERK2 microinjected into the cytoplasm§To whom correspondence should be addressed.
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detected in the nucleus using anti-phosphoERK anti-
bodies (Figures 1A and 1B). Translocation was rapid;
nuclear phosphorylated ERK2 was detected within 1
min after cytoplasmic injection. The antibodies also
stained the cytoplasm of injected cells, consistent with
previous findings that only a portion of the phosphory-
lated ERK2 accumulated in the nucleus (Reszka et al.,
1995; Cheng et al., 1996). Nuclear uptake of phosphory-
lated ERK2 was also observed following cytoplasmic
injection of Swiss 3T3 and human foreskin fibroblasts
(data not shown). Thus, indifferent cell lines both immor-
talized and primary, phosphorylation of ERK2 promotes
its accumulation in the nucleus.
Extracellular Stimuli Induce Nuclear
Uptake of ERK2
To confirm that microinjected unphosphorylated ERK2
was capable of translocating to the nucleus in response
to a stimulus, Myc-epitope tagged ERK2 was injected
and detected using an anti-Myc antibody. Unphosphor-
ylated Myc-ERK2 appeared in the nucleus of unstimu-
lated cells only transiently (5 min) after injection into the
cytoplasm (data not shown). Thereafter, it was seen in
the cytoplasm. However, it accumulated in the nucleus
when cells were stimulated with phorbol ester or serum
(data not shown). Unphosphorylated wild-type or ki-
nase-deficient K52R Myc-ERK2 injected in the cyto-
plasm remained there for hours (Figures 1G and 1H),
although the immunofluorescent signal became weak.
Translocation of this cytoplasmic protein to the nucleus
occurred upon stimulation with platelet-derived growth
factor up to 3 hr after injection (Figures 1I and 1J), indi-
cating that the injected protein could move to the nu-
cleus even hours after it was introduced into cells.
Thiophosphorylation of ERK2 Enhances
Its Nuclear Accumulation
The studies above indicated that phosphorylation of
ERK2 determined its intracellular distribution. However,
the duration of the immunofluorescent signal using
the anti-phosphoERK antibodies was short (data not
shown). This suggested that injected ERK2 was rapidly
dephosphorylated. To reduce its susceptibility to de-
phosphorylation by endogenous phosphatases, ERK2
was thiophosphorylated in vitro (Cassel and Glaser,
1982).Figure 1. Nuclear Translocation of ERK2 Microinjected into the Cy-
As with phosphorylated ERK2, thiophosphorylatedtoplasm of REF52 Cells
ERK2 translocated to the nucleus within minutes after(A and B) Phosphorylated ERK2 (1 mg/ml) was microinjected with
rat IgG at 1.5 mg/ml. Cells were fixed after 10 min and stained with cytoplasmic injection and remained there for at least 6
anti-IgG antibody to detect injected cells (A) and with anti-active hr (Figures 1C±1F). By 3 hr postinjection, half or more
ERK antibody to detect injected ERK2 (B). Pictures are representa- of the cells had nuclear staining, indicating a more per-
tive of 3±5 experiments of 50±150 cells.
sistent signal than observed for phosphorylated ERK2.(C±F) Thiophosphorylated ERK2 (3 mg/ml) was microinjected with
Similar results were obtained with thiophosphorylatedrat IgG at 2 mg/ml. Cells were fixed after 30 min (C and D) and 3 hr
K52R ERK2 and ERK1, although ERK1 was neither re-(E and F) and stained with the anti-IgG antibody (C and E) and
with the anti-active ERK antibody (D and F). Cells injected with tained as long nor as uniformly distributed within nuclei
thiophosphorylated K52R ERK2 showed similar nuclear accumula- (data not shown).
tion for at least 3 hr. To examine the nuclear retention of ERK2, unphos-
(G±J) K52R Myc-ERK2 (3.5 mg/ml) was microinjected with rabbit phorylated, phosphorylated, or thiophosphorylated ERK2
IgG at 3 mg/ml. Cells were unstimulated for 3 hr (G and H) or stimu-
was injected into the nucleus. Staining with the anti-lated with 16 ng/ml PDGF 3 hr after injection (I and J), then stained
phosphoERK antibody revealed that thiophosphory-with the anti-IgG antibody (G and I) and with the anti-Myc antibody
(H and J). For each test 50±150 cells were injected. latedwild-type (data not shown) or K52R ERK2 remained
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Figure 3. Nuclear Translocation of Unphosphorylated ERK2 Mi-
croinjected with Thiophosphorylated K52R ERK2 into the CytoplasmFigure 2. Thiophosphorylated ERK2 Injected in the Nucleus of
of REF 52 CellsREF52 Cells Remains Nuclear while Unphosphorylated ERK2 Is Ex-
(A±D) T183A,Y185F Myc-ERK2 (2.9 mg/ml) was microinjected withported
rabbit IgG at 4 mg/ml. Cells were stimulated with 0.35 mM TPA for(A±D) Thiophosphorylated K52R ERK2 (2 mg/ml) was microinjected
50 min (A and B) or unstimulated for 5 min (C and D), then stainedwith rat IgG at 2±3 mg/ml. Cells were fixed 30 min (A and B) and 2
with the anti-IgG antibody (A and C) and the anti-Myc antibody (Bhr (C and D) after injection and stained with the anti-IgG antibody
and D).(A and C) and with the anti-phosphoERK antibody (B and D). Wild-
(E and F) Thiophosphorylated K52R ERK2 (2 mg/ml) mixed withtype thiophosphorylated ERK2 behaved similarly.
K52R Myc-ERK2 (1.8 mg/ml) was microinjected with rat IgG at 2±3(E±H) K52R Myc-ERK2 (3.4 mg/ml) was microinjected with rabbit
mg/ml. Cells were fixed after 30 min and stained with anti-IgG (E)IgG at 2±3 mg/ml. Cells were fixed 5 min (E and F) and 2 hr (G and
and the anti-Myc antibody (F).H) after injection and stained with the anti-IgG antibody (E and G)
(G and H) Thiophosphorylated K52R ERK2 (1.8 mg/ml) was mixedand with the anti-Myc antibody (F and H). Similar results were ob-
with T183A,Y185F Myc-ERK2 (2.2 mg/ml) and microinjected with rattained with wild-type Myc-ERK2. For each panel 2±3 experiments
IgG at 4 mg/ml. After 30 min, cells were stained with the anti-IgGof 50±100 cells were performed.
antibody (G) and the anti-Myc antibody (H). Panels represent 3±5
experiments of 50±150 cells.
nuclear from shortly after (30 min; Figures 2A and 2B)
to at least 2 hr (Figures 2C and 2D) after injection into K52R ERK2 demonstrate that ERK2 activity is not neces-
sary for nuclear accumulation, consistent with earlierthe nucleus. In contrast, unphosphorylated K52R Myc-
ERK2 remained in the nucleus less than 5 min (Figures studies (Gonzalez et al., 1993; Lenormand et al., 1993).
2E and 2F) before beginning to redistribute to the cy-
toplasm. Immunofluorescence from unphosphorylated Phosphorylated ERK2 Facilitates Nuclear
Uptake of Unphosphorylated ERK2K52R ERK2 disappeared from the nucleus (Figure 2H),
while the coinjected IgG remained nuclear (Figure 2G). In contrast to our finding that phosphorylation of ERK2
was sufficient to induce its nuclear import, previous stud-Thiophosphorylation stabilized the nuclear localization
of ERK2. Furthermore, results with thiophosphorylated ies in transfected cells indicated that phosphorylation
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Figure 4. Gel Filtration and Equilibrium Sedi-
mentation of ERK2
His6-H176E L4A ERK2 was thiophosphory-
lated and His6-ERK2 was from the coex-
pression system. Proteins were treated with
phosphoprotein phosphatase 2A (PP2A) or
phosphotyrosine phosphatase 1 (PTP1) as in-
dicated and applied to Superdex G-75 (A).
Arrows indicate Stokes radii of the stan-
dard bovine serum albumin (36 AÊ ), ovalbumin
(33 AÊ ), chymotrypsinogen (21 AÊ ), and ribo-
nuclease A (16 AÊ ). Horizontal axis is the time
of elution. Phosphorylated (B) and unphos-
phorylated (C) ERK2 were sedimented to
equilibrium at 9000 rpm. The theoretical con-
centration gradients if only dimer (1) or mono-
mer (2) were present are indicated. Best-fit
lines to a monomer±dimer equilibrium model
and the distribution of the residuals are
shown.
of ERK2 was not necessary for its import (Lenormand translocated into the nucleus (data not shown). Trans-
location was short-lived, consistent with the dephos-et al., 1993). Therefore, we examined the distribution of
ERK2 in which both of the activating phosphoryla- phorylation of wild-type ERK2. Thus, nuclear transloca-
tion of K52R Myc-ERK2 was not due to overloading thetion sites T183 and Y185 were mutated. As expected,
T183A,Y185F Myc-ERK2 microinjected into the cyto- cell with ERK protein (Fukuda et al., 1997). However,
when unphosphorylated K52R Myc-ERK2 was coinjectedplasm translocated to the nucleus after stimulation of
cells with phorbol ester (Figures 3A and 3B). In the ab- with untagged thiophosphorylated kinase-deficient K52R
ERK2, rapid nuclear accumulation of unphosphorylatedsence of a stimulus, this mutant remained in the cyto-
plasm (Figures 3C and 3D). K52R Myc-ERK2 was observed, at 30 min (Figures 3E
and 3F) and for up to 3 hr. These results suggest thatIn spite of the fact that phosphorylation was sufficient
for nuclear import, phosphorylation was not required for phosphorylation of ERK2 facilitates the formationof ERK
complexes that are imported.stimulus-induced import whether protein was intro-
duced by transfection or microinjection. We considered
two possible explanations: 1) the stimulus caused nu-
clear import of unphosphorylated mutant ERK2 by a Phosphorylated ERK2 Forms Dimers
To determine if ERK2 oligomerizes, we subjected phos-mechanism dependent on the activity of endogenous
ERK2; or 2) phosphorylated ERK2 formed an import- phorylated and unphosphorylated ERK2 to gel filtration
on Superdex G75. Phosphorylated ERK2 eluted in twocompetent complex with unphosphorylated ERK2. If
ERK2 activity was required for nuclear uptake of coin- poorly resolved peaks with apparent Stokes radii of 35
and 27 AÊ (Figure 4A, top), consistent with the existencejected, unphosphorylated ERK2, then import would oc-
cur via an activity-dependent mechanism. If so, then of monomers and dimers. Unphosphorylated ERK2 eluted
as a single peak at 24AÊ (Figure 4A, next to bottom).either ERK2 phosphorylation or activity would be suf-
ficient for nuclear accumulation. If ERK2 activity was Dephosphorylation of ERK2 with either phosphothreo-
nine- or phosphotyrosine-selective phosphatases con-not required and instead phosphorylated, catalytically
defective K52R ERK2 was sufficient to induce import verted the faster eluting protein into the more slowly
eluting form (Figure 4A, middle panels). Thus, intercon-of unphosphorylated protein, then protein complexes
would be implicated. version of these two species is catalyzed by phosphory-
lation/dephosphorylation.To distinguish between these hypotheses, combina-
tions of wild-type and K52R ERK2 in phosphorylated To define the nature of the ERK2 complexes, phos-
phorylated and nonphosphorylated ERK2 were ana-and unphosphorylated states were injected into the cy-
toplasm. When a mixture of unphosphorylated K52R lyzed by equilibrium sedimentation. The data were mod-
eled on the basis of a system composed of two idealMyc-ERK2 together with phosphorylated untagged wild-
type ERK2 was injected, kinase-defective Myc-ERK2 solutes, a monomer of Mr 42,000 and a dimer of 84,000.
ERK2 Dimerization and Nuclear Translocation
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Comparison of the data to the model showed an excel-
lent fit with a random distribution of the residuals. Phos-
phorylated ERK2 sedimented primarily as an 84 kDa
species (Figure 4B) in multiple experiments. In contrast,
unphosphorylated ERK2 sedimented as a mixture of a
lesser amount of the 84 kDa and a greater amount of
the 42 kDa species, consistent with unphosphorylated
ERK2 existing primarily as a monomer (Figure 4C). Thus,
the first peak eluted from the gel filtration column is an
ERK2 dimer. Modeling the data as a two component
self-association system and using a molar extinction
coefficient of 45,000 for ERK2, the calculated dimer KD
for phosphorylated ERK2 was 7.5 nM. In contrast, the
dimer KD for unphosphorylated ERK2 was nearly 3000-
fold higher at approximately 20 mM.
We next tested the capacity of wild-type ERK2 to
form dimers with unphosphorylated ERK2 and mutants.
Phosphorylated wild-type ERK2 was mixed with un-
phosphorylated ERK2, K52R Myc-ERK2, or with the
phosphorylation site mutant T183A,Y185F Myc-ERK2.
ERK2 activity was detected in the anti-Myc immunopre-
cipitates of K52R ERK2 or T183A,Y185F ERK2 but not in
the immunoprecipitates of untagged unphosphorylated
ERK2 (Figure 5A). These data indicate that phosphory-
lated wild-type ERK2 can form dimers with either un-
phosphorylated wild-type or mutant ERK2.
As a final test of the capacity of phosphorylated ERK2
to mediate nuclear import of unphosphorylated ERK2,
we determined if phosphorylated ERK2 was sufficient for
import of the phosphorylation site mutant T183A,Y185F
ERK2. Although stimulation of cells caused the nuclear
accumulation of this mutant, T183A,Y185F Myc-ERK2
was found in the cytoplasm when microinjected alone
into either the cytoplasm or the nucleus or when coin-
jected with unphosphorylated wild-type ERK2 (Figures
3C and 3D; data not shown). On the other hand,
T183A,Y185F Myc-ERK2 coinjected with thiophosphor-
ylated untagged K52R ERK2 accumulated in the nucleus
(Figures 3G and 3H). Thus, nuclear translocation of
phosphorylation-defective ERK2 mutants occurs most Figure 5. Association of Phosphorylated and Unphosphorylated
likely as a consequence of the formation of dimers with ERK2
phosphorylated protein. ERK2 activity in anti-Myc and control immunoprecipitates of (A)
phosphorylated His6-tagged ERK2 mixed with unphosphorylatedTo determine if the interface detected in the crystal
ERK2, K52R Myc-ERK2, or T183A,Y185F Myc-ERK2 and (B) phos-structure was essential for dimerization, we character-
phorylated His6-ERK2 or ERK2D4 mixed with K52R Myc-ERK2 orized properties of mutants lacking residues at this inter-
T183A,Y185F Myc-ERK2 is shown. (C) Sedimentation equilibriumface (Figures 7A and 7B). Histidine 176 was mutated or
analysis of phosphorylated ERK2D4 with the best-fit line to a mono-
deleted either alone (H176E or deletion of P174-D177, mer±dimer equilibrium model. The theoretical concentration gradi-
called D4) or in combination with substitutions of two ent if only monomer was present is indicated. Phosphorylated ERK2-
or four of the leucine residues in L16 (L333,336E or D4L4A behaved in a similar manner.
L333,336,341,344A, called L4A ERK2). Phosphorylated
H176E L4A ERK2 and all other ERK2 dimer mutants
Dimerization Contributes totested had kinase activitycomparable towild-type ERK2
Phosphorylation-Dependent(data not shown), as reported previously for ERK2D4
Nuclear Localization(Robinson et al., 1996). Unlike wild-type ERK2, mutants
To assess the importance of dimerization on subcellularlacking H176, H176E L4A ERK2, and ERK2D4 behaved
localization of ERK2, ERK2 mutants that could not di-as monomers by ultracentrifugation and by gel filtration
merize were thiophosphorylated and microinjected intoeven when phosphorylated (Figures 4A [bottom] and
cells. When thiophosphorylated H176E L4A ERK2 was5C). Thiophosphorylated ERK2D4 coimmunoprecipitated
microinjected into the cytoplasm, like wild-type unphos-poorly with wild-type ERK2 (Figure 5B). Mutation of the
phorylated ERK2, the mutant appeared transiently inleucine residues on the interface alone was not sufficient
the nucleus and rapidly relocalized to the cytoplasm.to prevent dimerization (data not shown). These studies
In contrast to thiophosphorylated ERK2, however, theconfirm the location of the dimer interface identified in
the crystal structure. majority of H176E L4A ERK2 remained in the cytoplasm
Cell
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This hypothetical substrate was overlaid on the ERK2
kinase dimer. An extended region of the transcription
factor dimer following the phosphorylation sites within
the N-terminal domain and preceding the coiled coil
beginning at residue 156 of c-Fos is not shown to allow
an unimpeded view of the substrate binding region and
to emphasize the nature of the dimer±dimer symmetry.
Discussion
Mechanisms of Nuclear Localization of ERKs
Extracellular stimuli induce the nuclear translocation of
wild-type, kinase-deficient, and phosphorylation site
mutants of ERK1 and ERK2 (Gonzalez etal., 1993; Lenor-
mand et al., 1993; Cheng et al., 1996). To investigate
requirements for their nuclear translocation, we microin-
jected ERKs into cells without activating the upstream
signal transduction pathway. Under these conditions
phosphorylated ERKs, wild-type and kinase-deficient,
accumulate in the nucleus. Unphosphorylated ERKs re-
main primarily in the cytoplasm but translocate to the
nucleus in response to a stimulus. These studies demon-
strate that phosphorylation of ERKs is sufficient for their
nuclear translocation and that kinase activity is not re-
quired.
ERK2 dimerizes in a phosphorylation-dependent man-
ner. ERK2 dimers may be composed of two phosphory-
lated molecules or one phosphorylated and one unphos-
phorylated molecule, a hemiactive dimer. The same is
Figure 6. Intracellular Distribution of Thiophosphorylated H176EL4A true of ERK1. Thus, we conclude that phosphorylation
ERK2
of at least one of the molecules in the dimer is both
(A±F) Thiophosphorylated H176E L4A ERK2 (4 mg/ml) was microin- necessary and sufficient for nuclear localization of heter-jected into the cytoplasm with mouse IgG at 4 mg/ml. Cells were
ologously expressed ERK. Import of hemiactive dimersfixed 30 min (A and B), 1 hr (C and D), and 1.5 hr (E and F) after
resolves the apparent paradox that phosphorylation siteinjection and stained with the anti-IgG antibody (A, C, and E) and
with the anti-phosphoERK antibody (B, D, and F). Two experiments mutants of ERKs expressed from transfected plasmids
of 100±150 cells were performed for each. are translocated in stimulated cells. Mutants that fail
to dimerize accumulate less well in the nucleus when
phosphorylated. This provides strong evidence that di-
from 30 min to 1.5 hr after injection (Figures 6A±6F). merization is part of the physiological mechanism for
Faint nuclear staining was also noted. The molecules nuclear translocation of ERKs. Because certain actions
detected in the cytoplasm were phosphorylated be- of ERKs such as induction of neurites in PC12 cells are
cause they were recognized by the anti-active ERK anti- dependent on their nuclear entry (Traverse et al., 1992;
body. Thiophosphorylated ERK2D4 also did not accu- Marshall, 1995; Robinson et al., submitted), the biologi-
mulate in the nucleus, although the immunofluorescent cal significance of dimerization is great.
signal from this mutant was weak. Thus, ERK2 mutants The subcellular localization of ERKs likely arises from
that do not homodimerize are found primarily in the the concerted effects of regulated nuclear import, regu-
cytoplasm. lated nuclear export, and regulated cytoplasmic reten-
tion. Proteins smaller than 40±50 kDa readily diffuse into
the nucleus (Wen et al., 1995; GoÈ rlich and Mattaj, 1996),Model for Substrate Dimer-Kinase
Dimer Interaction suggesting that monomeric ERKs enter the nucleus by
diffusion. Our data support the idea that ERKs may enterThe 2-fold symmetry of the kinase dimer matches the
2-fold symmetry or pseudosymmetry of dimeric coiled- freely by diffusion, because most of the unphosphory-
lated proteins tested were found transiently in the nu-coil transcription factors. A plausible interaction be-
tween a MAP kinase dimer and the substrate dimer Fos- cleus, although they rapidly relocalized to the cyto-
plasm. However, active dimeric proteins, which are tooJun (Knighton et al., 1991; Glover and Harrison, 1995)
could lead to the simultaneous phosphorylation of sites large for unrestricted diffusion into the nucleus, rapidly
accumulate in the nucleus following introduction intoin both substrate molecules as shown in the model (Fig-
ure 7C). The model was constructed using substrate the cytoplasm. Although ERKs may dissociate and reas-
sociate following nuclear entry, the data are consistentbinding interactions defined by protein kinase inhibitor
peptide contacts with cAMP-dependent protein kinase with the possibility that they are actively imported.
The putative nuclear localization signal need not be(Knighton et al., 1991) fused through a loop to the coiled
coil from the Fos-Jun dimer (Glover and Harrison, 1995). intrinsic to monomeric ERKs but may arise from the
ERK2 Dimerization and Nuclear Translocation
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Figure 7. ERK2 Dimers
(A) The structure of the ERK2 dimer shows the active sites on the same face and the substrate binding groove distal to the dimer axis. The
b strands are in green, a helices in blue, and L16 and the MAP kinase insert in magenta. Phosphorylated residues, T183 and Y185, are
indicated by P-T and P-Y in yellow.
(B) Leucine residues 333, 336, and 344 in L16 contact each other in the dimer. H176 in the phosphorylation lip of one molecule and E343 in
L16 of the other form an ion pair.
(C) Model of a dimeric transcription factor bound to an ERK2 dimer. The N terminus of each substrate monomer (red and green) fits into the
extended substrate binding groove distal to the dimer interface; binding of the extended region surrounding the phosphorylation site of each
substrate to the binding sites on the kinase dimer should be feasible with the constraints of the substrate dimer. The kinase dimer is shown
as a worm diagram with transparent surface. The leucine zipper of the c-Fos:c-Jun dimer is shown as pink and blue helices. Model was
constructed using the coordinates of ERK2-P2 (Canagarajah et al., 1997), the coordinates of c-Fos residues 156±198 and c-Jun residues
280±322 from the c-Fos:c-Jun heterodimer (Protein Data Bank file 1fos.ent [Glover and Harrison, 1995]), and residues 6±24 of the protein
kinase inhibitor bound to cyclic-AMP-dependent protein kinase (Protein Data Bank file 1atp.ent [Knighton et al., 1991]). (A) and (B) were
generated in MOLSCRIPT (Kraulis, 1991) and rendered in RASTER3D (Bacon and Anderson, 1988). (C) was generated in GRASP (Nicholls et
al., 1991). The protein kinase inhibitor and c-Fos:c-Jun dimer coordinates were linked through a 10 residue loop.
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association of phosphorylated ERKs with other pro- which dimerization influences the nuclear import of
ERK2 without affecting its kinase activity. Dimerizationtein(s), which are imported by a piggy-back mechanism
(Jans, 1995; GoÈ rlich and Mattaj, 1996). For example, is not necessary for kinase activity because ERK2 activ-
ity is concentration independent (Robbins et al., 1993)ERKs are known to associate with the substrate Rsk,
which also enters the nucleus upon activation (Chen and dimerization-defective mutants have activity com-
parable to wild type. The crystal structure shows thatet al., 1992; Hsiao et al., 1994; Zhao et al., 1996). The
ERK±Rsk complex may be recognized for import once dimerization does not obstruct the active sites (Cana-
garajah et al., 1997).Rsk is phosphorylated by ERKs. Our data indicate, how-
ever, that ERK activity is not required for its nuclear The physical basis for dimerization has been deduced
from the crystal structure of active ERK2 and confirmedaccumulation. Therefore, ERK homodimerization may
be at least as significant in inducing nuclear uptake. by mutagenesis. In active ERK2, a network of charge±
charge interactionsare created between thephosphory-Consistent with this conclusion, the dimerization-defec-
tive but active mutant H176E L4A ERK2 remains in the lation lip and L16 within the C-terminal extension to the
catalytic core. Leucine residues on the surface of L16cytoplasm. Dimerization of ERKs may expose a binding
site for a protein containing a nuclear localization signal, interact with the same residues of a second ERK2 mole-
cule. The ERK2 phosphorylation lip and regions inter-or the dimers may bind directly to a component of the
import machinery. Alternatively, ERKs may be imported acting with it, including L16, become disordered in mu-
tants lacking the tyrosine phosphorylation site (Zhangby a less-well-characterized mechanism (e.g., Pollard
et al., 1996). et al., 1995). The low stability of the lip and L16 explains
why a phosphorylated ERK2 molecule induces an un-Phosphorylated and unphosphorylated ERKs are ex-
ported at different rates following microinjection into phosphorylated ERK2 molecule or mutant to dimerize
with it.the nucleus, consistent with regulation of their nuclear
export. The ERK2 dimer interface contains a putative We find that p38, ERK1, and JNK/SAPK also form
homodimers (unpublished data). However, they appar-nuclear export sequence (MELDDLPKEKLKEL) (Wen et
al., 1995). Dimerization of ERKs may block their nuclear ently form heterodimers poorly. Preliminary results sug-
gest that ERK1/ERK2 heterodimers are more readily dis-export not only because as dimers they are too large
for diffusion through nuclear pores, but also because sociable than hemiactive ERK2. The dimer interfaces in
the two MAP kinases ERK2 and p38, for which structuraldimerization masks this putative export signal. Replace-
ment of this sequence does not result in nuclear reten- data are available (Zhang et al., 1994; Wilson et al., 1996;
Wang et al., 1997), are different in conformation andtion of unphosphorylated protein, suggesting that it is
not sufficient to control the localization of ERK2. sequence, making heterodimerization between MAP ki-
nase family members unlikely. On the other hand, theFinally, the regulated distribution of ERKs may involve
retention of unphosphorylated ERKs in the cytoplasm many JNK/SAPK isoforms (DeÂ rijard et al., 1994; Kallunki
et al., 1994; Gupta et al., 1996) may heterodimerize. In(Fukuda et al., 1997) or phosphorylated ERKs within
the nucleus. A nuclear export signal found on the ERK this regard, a p38 splice variant, Mxi2, cloned by its two-
hybrid interaction with the Myc partner Max (Zervos etupstream activator MEK1 may tether ERKs in the cyto-
plasm; feedback phosphorylation of MEK by activated al., 1995) is truncated prior to L16 and may therefore
not dimerize. As a result, Mxi2 may interfere with theERK may allow ERKs to escape to the nucleus (Fukuda
et al., 1997). This mechanism is compatible with our phosphorylation of dimeric transcriptional regulators to
which it binds.findings; however, it is not sufficient to account for our
results that demonstrate nuclear accumulation of ki-
nase-deficient phosphorylated, but not unphosphory-
Physiological Impact of MAP Kinase Dimerizationlated, ERKs in the absence of cell stimulation. Nor is
Many MAP kinase substrates are dimers, including basicit likely to account for the cytoplasmic localization of
helix-loop-helix and leucine zipper proteins and steroidphosphorylated H176E L4A ERK2, which has kinase ac-
receptors (Hunter and Karin, 1992; Seth et al., 1992;tivity not significantly different from wild-type ERK2.
Cheng et al., 1993; Karin, 1995; Mangelsdorf et al., 1995;
Kallunki et al., 1996). MAP kinase dimers may activate
substrate dimers through a single interaction. The struc-Mechanisms of MAP Kinase Dimerization
Dimerization upon activation is a property common to ture of the MAP kinase dimer together with data on the
interactions between protein kinases and their sub-members of the MAP kinase family. The monomer±dimer
equilibrium for ERK2 is shifted strongly in favor of dimers strates lead to a compelling model for the interaction
between a MAP kinase dimer and a dimeric transcriptionupon phosphorylation, with a KD of 7.5 nM for dissocia-
tion of the phosphorylated ERK2 dimer and a KD of 20 mM factor. The kinase active sites are oriented on one face
of the dimer, and the dimer has the same symmetryfor dissociation of the unphosphorylated ERK2 dimer.
Using an estimate of the intracellular concentration of as transcription factor substrates (Figure 7). Residues
N-terminal to the phosphoacceptor site of the substrateERK2 in the high nanomolar range (Ferrell, 1996), the
protein should exist primarily as a dimer in stimulated bind to a surface groove near helices D and G of the
kinase (Knighton et al., 1991; Kallunki et al., 1994;cells and as a monomer in resting cells. Although we
have been unable to demonstrate dimers in whole-cell Canagarajah et al., 1997). Residues C-terminal to the
phosphoacceptor site of substrate bind near the phos-lysates, the biochemical data are unambiguous that
phosphorylated ERK2 is a dimer in vitro. Furthermore, phorylation lip. ERK2 dimerization also involves the
phosphorylation lip. Thus, a dimeric transcription factorthe nuclear import data is compelling evidence that
dimers occur in vivo. These data suggest a model in may dock onto the ERK2 dimer, with the N terminus
ERK2 Dimerization and Nuclear Translocation
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of each chain bound to the peptide substrate binding mutagenesis impairs nuclear accumulation. Dimeriza-
groove. In this binding mode, the 2-foldaxis of symmetry tion of these kinases introduces additional complexity
of the transcription factor is parallel with the axis of in their regulation and their access to and interaction
symmetry of the kinase. with downstream targets and creates distinct thresholds
The fact that dimers may be composed of phosphory- for target activation. Thus, with the finding that MAP
lated and unphosphorylated MAP kinases as a mixture kinases dimerize comes the discovery of a new para-
of fully activeand hemiactive dimers may have an impact digm in our understanding of these pleiotropic protein
on the time course, the threshold for activation, and the kinases.
efficacy of regulation of downstream substrates (see
Experimental ProceduresChi-Ying and Ferrell, 1996). A single interaction of hemi-
active dimeric kinase with dimeric substrate will phos-
Proteinsphorylate only one subunit of the substrate dimer. With
ERK2 mutants were created using the QuikChange kit (Stratagene,weak stimuli or during the decay of a response, the
La Jolla, CA). Unphosphorylated and phosphorylated His6-tagged
majority of ERKs may be in hemiactive dimers. proteins were expressed and purified on Ni21-NTA agarose and
Dimerization of substrates has already been shown MonoQ (Robbins et al., 1993; Mansour et al., 1994; Khokhlatchev
to influence substrate recognition by a member of the et al., 1997). ERK2 was dialyzedagainst 43 buffer A (12.5 mM HEPES
(pH 7.3), 100 mM KCl, 6.25% glycerol) and concentrated to 12±16MAP kinase family (Kallunki et al., 1994; Karin, 1995;
mg/ml in a Microcon 30 concentrator (Amicon, Beverly, MA). Pro-Gupta et al., 1996). c-Jun is phosphorylated as a conse-
teins were frozen in liquid nitrogen and stored at 2808C in smallquence of its tight interaction with JNK/SAPK (Hibi et
aliquots.
al., 1993; Kallunki et al.,1994). c-Jun forms heterodimers To prepare thiophosphorylated and Myc epitope±tagged ERK2
with other related factors, some of which lack the do- proteins, ERK2 andmutants were subclonedinto pGEX-KG modified
main necessary for tight association with JNK/SAPK so that after thrombin cleavage recombinant proteins contained
(Karin, 1995; Kallunki et al., 1996). Subunits of Jun heter- only two additional N-terminal amino acids. In some cases, a Myc
epitope (EQKLISEEDL) was inserted between the thrombin cleavageodimers that lack the JNK/SAPK-binding domain, such
site and the ERK2 initiator methionine. Glutathione-S-transferaseas JunD, are phosphorylated only if they heterodimerize
(GST)-tagged proteins (Guan and Dixon, 1991) were cleaved withwith Jun monomers that have the JNK/SAPK-binding
thrombin (Ngai and Chang, 1991), phenylmethylsulfonylfluoride
site (Kallunki et al., 1996). (PMSF) was added to 0.1 mM, and the mixture was passed twice
The phosphorylation of the nonJNK/SAPK-binding over reduced glutathione beads. Kinases were purified on MonoQ,
subunit of a Jun heterodimer, e.g., JunD, may be cata- dialyzed against buffer A, and concentrated as above. ERK2 (30 mg/
lyzed not by the tightly bound JNK/SAPK monomer but ml) was activated in vitro using coexpressed GST-MEK2 (Khokhlat-
chev et al., 1997) at 0.5 mg/ml and 200 mM ATPgS (Boehringer) inrather by the second subunit of the JNK/SAPK dimer.
20 mM HEPES (pH 7.5), 1 mM dithiothreitol (DTT), 10 mM MgCl2, 1This should result in a multi-tiered activation of sub-
mM benzamidine, 150 mM PMSF, 0.2 mg/ml pepstatin A, 0.26 mg/mlstrates depending upon the number of substrate-kinase-
leupeptin, 20 mM NaCl, and 15% glycerol for 1±2 hr. 50 mM NaCl
binding sites, functional active sites in the kinase dimer, was added and the kinase was purified on glutathione beads and
and competent phosphoacceptor sites in the substrate. MonoQ, dialyzed, and concentrated 15- to 20-fold in Centriprep 30
Transcription factors that contain only one subunit that concentrators (Amicon). Activated kinases ranged from 30%±95%
binds tightly to the kinase should be less sensitive to active based on a specific activity of 2±3 mmol/min/mg for active
protein and on gel shift analysis (Khokhlatchev et al., 1997).activation than those that contain two kinase-binding
subunits. Hemiactive kinase dimers should work less
Microinjectioneffectively on dimeric substrates due to the requirement
REF 52, Swiss 3T3, or human foreskin fibroblasts were plated on
for more than one collision with substrate to phosphory- glass coverslips at 4±4.5 3 103/cm2 in Dulbecco's modified Eagle
late the sites. When fully active dimers predominate, the medium (DMEM) and 10% fetal bovine serum (FBS) (GIBCO BRL).
odds of inducing certain activities, e.g., like those of After 24±48 hr, cells were placed in starvation medium (DMEM with
c-Jun/JunD heterodimers, would increase substantially. 0.1% FBS) for 48 hr prior to injection. ERK2 was diluted with sterile
water to a buffer A concentration of 0.7±13. Carrier IgG (Sigma)Thus, differential activation of dimeric substrates by di-
was added to a final concentration of 1.5±4 mg/ml. Injections weremeric kinases is a mechanism for generating distinct
performed using a Zeiss I105 inverted microscope equipped withresponse thresholds because substrates are differen-
thermostatic chamber, Narishige model 202 micromanipulator, and
tially sensitive to the magnitude of the signal that regu- Eppendorf 5242 injector.
lates the cascade.
Homodimerization also has implications in the mecha- Immunofluorescence
nism of inhibition of downstream events by mutants Cells fixed in 3.7%formaldehyde in phosphate-buffered saline (PBS)
and permeablized either in cold methanol for 5 to 10 min or inthat lack kinase activity or phosphorylation sites. These
0.2% Triton X-100 for 10 min were stained with either the anti-mutants are used as dominant inhibitors of their respec-
phosphoERK antibody (Promega) or an antibody to the Myc epitopetive MAP kinase pathways (Sontag et al., 1993; Korten-
(9E10, SantaCruz) andthen with a mixture of fluorescein-conjugated
jann et al., 1994; Minden et al., 1995). Events that depend goat antibody to rabbit or rat IgG and lissamine rhodamine±
on phosphorylation of multimeric substrates will be conjugated goat antibody to mouse IgG in PBS/bovine serum albu-
more sensitive to inhibition by overexpression of non- min (Jackson ImmunoResearch) (Cheng et al., 1996). In some experi-
functional mutants than will those involving monomeric ments with Myc-ERK2, cells were fixed in 100% methanol at 2208C
or methanol:ethanol (95:5) for 30 min at 258C.substrates.
Gel Filtration and Analytical UltracentrifugationConclusions
Proteins (0.5±3 mg/ml in 25±100 ml) with or without phosphatase
Phosphorylation of ERKs is sufficient to induce their treatment (Khokhlatchev et al., 1997) were loaded on Superdex G-75
nuclear translocation independently of their kinase ac- equilibrated in buffer A and eluted with buffer A. Low molecular
tivity and of extracellular stimuli. Phosphorylated ki- weight calibration proteins (Pharmacia) were used. Highly purified
ERK proteins (0.4 mg/ml) dialyzed against buffer A with 0.9 mM DTTnases form homodimers; disruption of dimerization by
Cell
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were analyzed by equilibrium sedimentation in a Beckman XL-A mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci.
USA 93, 10078±10083.analytical ultracentrifuge. Aliquots (100 ml) were centrifuged at 9,000
or 12,000 RPM at 277 K in an An60Ti rotor (Beckman). The cells Chou, S.-y., Baichwal, V., and Ferrell, J.E., Jr. (1992). Inhibition of
were scanned at280 nm. Data points are the average of five readings c-Jun DNA binding by mitogen-activated protein kinase. Mol. Biol.
at 0.001 cm intervals through the sample column. The endpoint was Cell 3, 1117±1130.
reached when multiple scans did not change over 4 hr. The data DeÂ rijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin,
was modeled using Beckman XL-A Data Analysis Software version M., and Davis, R.J. (1994). JNK1: a protein kinase stimulated by UV
3.0 running in Origin version 3.78 with a calculated solvent density light and Ha-Ras that binds and phosphorylates the c-Jun activation
of 1.0128 g/ml. The partial specific volume of the molecule, 0.7305 domain. Cell 76, 1025±1037.
ml/g, was calculated from the amino acid composition (Zamyatnin,
Durschlag,H. (1986). Specific volumes of biologicalmacromolecules1972; Durschlag, 1986).
and some other molecules of biological interest. In Thermodynamic
Data for Biochemistry and Biotechnology, H.-J. Hinz, ed. (Berlin:
Immunoprecipitation Springer-Verlag), pp. 45±128.
Phosphorylated or unphosphorylated wild-type His6 ERK2 was incu-
Ferrell, J.E., Jr. (1996). Tripping the switch fantastic: how a proteinbated with wild-type or mutant Myc-ERK2 and immunoprecipitated
kinase cascade can convert graded in puts into switch-like outputs.with rabbit anti-Myc IgG (SC-789, Santa Cruz) or control IgG and
TIBS 21, 460±466.protein A-Sepharose beads (Frost et al., 1996). Beads were washed
Frost, J., Xu, S., Hutchison, M., Marcus, S., and Cobb, M.H. (1996).with buffer A with no additions, with 0.5% Triton X-100, with 0.4
Actions of Rho family small G proteins and p21-activated proteinM NaCl, and with 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM
kinases on mitogen-activated protein kinase family members. Mol.benzamidine, and 1 mM DTT; bound activity was assayed with my-
Cell. Biol. 16, 3707±3713.elin basic protein (Sigma). Counts per minute from control reactions
Fukuda, M., Gotoh, Y., and Nishida, E. (1997). Interaction of MAPwere subtracted. Phosphorylated wild-type or D4 His6 ERK2 was
kinase with MAP kinase kinase: its possible role in the control ofincubated with Myc-ERK2 for 2 hr at 308C and adjusted to 10 mM
nucleocytoplasmic transport of MAP kinase. EMBO J. 16, 1901±NaCl, 100 mM KCl, 0.01% Triton X-100, and 7.2% glycerol. Proteins
1908.were immunoprecipitated with rabbit anti-Myc IgG or with normal
rabbit IgG in the presence of 0.2 mg/ml cytochrome C. Beads were Gille, H., Sharrocks, A.D., and Shaw, P.E. (1992). Phosphorylation
washed once with buffer A, three times with 0.4 M NaCl and 1% of transcription factor p62TCF by MAP kinase stimulates ternary
Triton X-100 in buffer A, and once with 20 mM HEPES (pH7.5), 10 complex formation at c-fos promoter. Nature 358, 414±416.
mM MgCl2, 1 mM benzamidine, and 1 mM DTT, and bound activity Glover, J.N.M., and Harrison, S.C. (1995). Crystal structure of the
assayed as above. heterodimeric Bzip transcription factor c-Fos-c-Jun. Nature 373,
257±261.
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